Abstract: The present invention relates to mutated factor (FX) polypeptides and uses thereof for the treatment of haemophilia. In particular, the present invention relates to a mutated factor X (FX) polypeptide which comprises a heavy chain wherein at least one amino acid residue at position 401 or 408 is mutated.

Abstract: The present invention relates to T-cell receptors (TCR) that recognize pancreatic betacell epitopes and uses thereof for the diagnosis and treatment of diabetes.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of acute myeloid leukemia. In particular, the present invention relates to a method for treating NPM-1-driven acute myeloid leukemia (AML) in a subject in need thereof comprising administering the subject with a therapeutically effective amount of at least one arsenic compound and with a therapeutically effective amount of at least one retinoid.

Abstract: The invention relates to a method for increasing the yield and biomass of a plant, by means of an increase in the expression of the L-aspartate oxidase in the plant. The method according to the invention allows an increase in the photosynthetic capacities of the plants as a result of an increase in the quantities of NAO and the derivatives thereof in said plants. The invention relates to the plants produced by such a method.

Abstract: The present invention relates to the Compound of following formula (I): or a pharmaceutically acceptable salt thereof. The present invention also relates to a pharmaceutical composition containing such a compound and a method for preparing such a compound.

Abstract: Disclosed are agents inhibiting the interaction between CFH and CD11b/18, as well as the use of such agents, in particular for treating inflammatory disorders, such as age-related macular degeneration.

Abstract: The present invention concerns a compound of formula (I), or one of its pharmaceutically acceptable salts, especially for use as inhibitors of the ERK kinase activity in particular ERK2 activity, it also concerns prodrugs of these compounds.

Abstract: The present Inventors demonstrated that the RelB subunit of NF?B plays a crucial role in promoting cell migration. More precisely, they identified that this pro-migratory activity is mediated by the activation of the NF?B pathway through RelB phosphorylation at serine 472. In a first aspect, the present invention proposes to monitor the activation of the NF?B pathway by following the phosphorylation status of said serine. Also, the present invention discloses methods and kits for prognosing the evolution of a disease involving cell migration in a subject—treated or not—suffering thereof, based on the detection of said RelB-S472 phosphorylation.

Abstract: The present invention relates to methods and pharmaceutical compositions for the treatment of systemic mastocytosis. The inventors showed the effect of KPT-251 treatment on SCF-dependent human Mast cell (MC) line without KIT mutation (WT ROSA) and on two factor-independent MC lines with KIT mutations : ROSA ? 417-419 insY and ROSA D816V. KPT is a Selective Inhibitor of Nuclear Export (SINE) that specifically inhibits the activity of the exportin-1 (XPO1). KPT-251 treatment induces minimal toxicity in non-cancerous hematopoietic cells both in vitro and in vivo. In particular, the present invention relates a method of treating systemic mastocytosis in patient in need thereof comprising administering to the patient a therapeutically effective amount of a XPO1 inhibitor.

Abstract: The invention, according to an aspect thereof, relates to a device (60) for laser micromachining a sample made of a given material, which includes a focusing module enabling a nondiffracting beam to be generated from a given incident beam, said nondiffracting beam being focused along a focusing cylinder that is oriented generally along the optical axis of the focusing module, means (601) for transmitting at least one first light pulse (11) suitable for generating, after said focusing module focuses in the sample, a plasma of free charges by multiphotonic absorption in a volume of the sample located on the side surface of said focusing cylinder.

Abstract: An optically transparent electromagnetic shield assembly comprising an electrical connection device with variable electrical resistance. The electrical connection device electrically connects a conductive two-dimensional structure, which covers a transparent substrate, to a shell portion which is electrically conductive. The resistance of the connection device can be adjusted, either initially for a detection system for which the shield assembly is intended or in real time while the shield assembly is in use, according to an RF radiation intensity.

Abstract: The invention is directed to the field of gene therapy, i.e. gene delivery into target cells, tissue, organ and organism, and more particularly to gene delivery via viral vectors. The inventors showed that it is possible by chemical coupling to modulate the coupling of a ligand in the surface of the capsid of AAV, for example AAV2 and AAV3b. In particular, the present invention relates to a recombinant Adeno-Associated Virus (rAAV) vector particle having at least one primary amino group contained in the capsid proteins, chemically coupled with at least one ligand L, wherein coupling of said ligand L is implemented through a bond comprising a —CSNH— bond and an optionally substituted aromatic moiety. Particularly, the inventors tested the chemical coupling of mannose ligand on AAV2 for subretinally injection to rats.

Abstract: A method for producing a porous silicone material including the following steps: 1) implementing a direct emulsion E of silicone in water including: A) a silicone base A crosslinkable by polyaddition or polycondensation; B) at least one nonionic silicone surfactant B having a cloud point between 10 and 50° C.; C) optionally, at least one catalyst C; and D) water; 2) heating the emulsion E to a temperature greater than or equal to 60° C. to obtain a porous silicone material; and 3) optionally, drying the porous silicone material.

Abstract: The present invention relates to the use of a nucleic acid molecule encoding a first reporter gene, bordered by at least one first pair and one second pair of sequences targeting a site-specific recombinase in order to detect cells of a mammal infected with a virus responsible for an immunodeficiency.

Abstract: According to a first aspect, the present disclosure relates to a digital holography device (100) for full-field blood flow imaging of ocular vessels of a field of view of a layer (11) of the eye (10). The device comprises an optical source (101) configured for the generation of an illuminating beam (Eobj) and a reference beam (ELO), and a detector (135) configured to acquire a plurality of interferograms (I(x,y,t)) wherein an interferogram is defined as the signal resulting from the interference between the said reference beam (ELO) and a part of said illuminating beam (Eobj) that is backscattered from said layer (11).

Abstract: An antenna assembly, comprising: a single substrate having a lower surface and an upper surface; an isotropic source of spherical electromagnetic waves configured for emitting surfaces waves on the upper surface; a ground plane formed on the lower surface comprising a metallic deposit on the entire lower surface; an antenna element formed on the upper surface comprising a periodic patterns metasurface formed on the substrate by a texture of subwavelength patches, the antenna element comprising: a first-scale metasurface defined by a two-dimensional alternation of metal or metamaterial patches having closely spaced vertices in each contiguous element to form small gaps; a plurality of switches disposed in the gap between the vertexes of the patches, each switch permitting to connect several patches through the vertexes for defining a second-scale metasurface having a pattern thus forming the antenna element; wherein each patch has dimensions which do not depend on the frequency of the waves to be radiated,

Abstract: The present invention relates to a vector which comprises a nucleic acid sequence encoding for the frataxin (FXN) gene for use in the prevention and treatment of neurological phenotype associated with Friedreich ataxia in a subject in need thereof.

Abstract: The present invention relates to a pharmaceutical combination product comprising: a liposomal formulation exclusively containing a LPS; and at least one cytotoxic compound. It also relates to its use as an anti-tumour therapy.

Abstract: The invention proposes a device for analyzing nucleic acid molecules (M), comprising: —a bead (20), on which one molecule can be anchored at one end, —a surface (520), on which the molecule can be anchored at the other end, —an actuator (30), adapted to cause the bead to move relative to said surface in one direction, —a sensor (50), adapted to measure a distance between the bead and the surface, the device further comprising a well (11), having an axis (X-X) extending along the direction of motion of the bead and a bottom (110) formed by said surface, said well being filled with electrically conductive solution (40), and receiving the bead, the sensor being adapted to measure an impedance of the well, depending on a distance between the bead and the surface, to determine, the distance between the bead and the surface.

Abstract: An electronic device for measuring a speed of flow of a fluid that includes at least two electroacoustic transducers adapted for emitting and/or receiving acoustic signals through the flow of the fluid, the electronic device being adapted for determining a measurement of the speed of flow of the fluid from the characteristics of an acoustic signal emitted and one or more acoustic signals received, these received acoustic signals corresponding to reflections of the emitted acoustic signal.